Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (21.4), the stock would be worth ¥14.84 (0% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 21.4 | ¥14.84 |
0%
|
| 3-Year Average | 21.4 | ¥14.84 |
0%
|
| 5-Year Average | 18.5 | ¥12.84 |
-13%
|
| Industry Average | 26.2 | ¥18.19 |
+23%
|
| Country Average | 28.8 | ¥20.01 |
+35%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥26.6B
|
/ |
Apr 2026
¥1.2B
|
= |
|
|
¥26.6B
|
/ |
Dec 2026
¥2.2B
|
= |
|
|
¥26.6B
|
/ |
Dec 2027
¥2.5B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
L
|
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
|
27.4B CNY | 21.4 | 32.9 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 45.5 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 13.8 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 19.8 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 12.9 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 18.3 | 25.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 10.7 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 23.7 | 44.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 30.1 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 9.8 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 15.1 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Lepu Medical Technology Beijing Co Ltd
Glance View
Lepu Medical Technology Beijing Co Ltd. was born in the vibrant landscape of China's rapidly evolving healthcare industry. Established in 1999, the company has grown into a formidable player in the medical device sector. It carved its niche by focusing on cardiovascular interventions, technological innovations, and pharmaceuticals. At its core, Lepu Medical thrives on leveraging its research and development expertise to create products that cater to a broad spectrum of medical needs, particularly in the cardiovascular domain. They manufacture and distribute a wide range of medical devices which include coronary stents, pacemakers, and other related products, enabling them to secure a strong foothold in both domestic and international markets. Revenue generation for Lepu Medical is a multifaceted process that leverages the company's comprehensive vertical integration strategy. The company has strategically developed a robust portfolio not only in medical devices but also in pharmaceuticals and healthcare services. This diversified offering allows them to capture value across the entire patient care continuum—from device manufacturing and pharmaceuticals to post-operative care and services. By continually investing in innovation and expanding their reach through strategic partnerships and acquisitions, Lepu Medical ensures a consistent revenue stream, reinforcing its position within the global healthcare landscape. The company's commitment to quality and technological advancement keeps it competitive, propelling its growth across various health sectors.
